2018 Speakers

For the past 20 years, Glen has focused on the development and commercialization of technologies to address the unmet needs of patients with severe lung diseases. He has co-founded, built and sold three medical device companies. Pulmonx develops and markets minimally invasive technologies for the diagnosis and treatment of patients with severe emphysema. Prior to…

Ted Omachi is a Medical Director in the Product Development Immunology group at Genentech, focusing on late-stage development in respiratory and allergic diseases. He joined Genentech in 2013, starting in the Medical Affairs group before transitioning to Product Development in 2015. At Genentech, he has served as Clinical Science Team Leader, Medical Monitor and Medical…

Sally Seymour received a medical degree from the University of Cincinnati. She did her internship and residency training in internal medicine and fellowship training in pulmonary and critical care medicine at the University of Cincinnati. She joined the FDA as a Medical Officer in 2003. She is currently the Deputy Director for Safety in the…

Marc Moss is the Roger S. Mitchell Professor of Medicine and Vice Chair of Clinical Research for the Department of Medicine at the University of Colorado School of Medicine. For more than 17 years, Dr. Moss has received continuous NIH funding as a principal investigator, and his research has been published in high impact journals.…

Kevin Kinsella has been investing in early-stage technology companies for over thirty years, through Avalon Ventures, a venture capital fund he founded. These companies have been responsible for bringing to market several multibillion-dollar drugs for cancer, rheumatoid arthritis, cystic fibrosis, the Apple iPhone touch-screen, Big Data software to discover oil and gas, cloud computing, AI…

Jason Chien currently serves as the Gilead global lead for respiratory viruses. In this role, Jason helps Gilead define the overall commercial and development strategy for addressing the respiratory virus related unmet need in adults and children. Prior to joining Gilead in 2011, Jason was on faculty at the University of Washington and at Fred…

Dr. Van Goor is a research and development leader with expertise in protein folding and ion channel function as applied to discovery and development of breakthrough therapeutics for cystic fibrosis. He has a strong background in applying biological approaches (assay development, screening, molecular biology, and pharmacology) to drug discovery and advancing successful compounds from lab…